Eisai Licenses ISPRI Toolkit

Eisai Licenses ISPRI Toolkit

PROVIDENCE, RI, December 20, 2023 /PRNewswire/ — EpiVax, Inc. (“EpiVax”), an internationally recognized leader in the field of immunogenicity, today announced that Eisai Co. Ltd. (“Eisai”) has licensed EpiVax’s ISPRI toolkit for immunogenicity risk assessment of...
EpiVax: 25 years of Fearless Science

EpiVax: 25 years of Fearless Science

  EpiVax is celebrating 25 years of innovative immunoinformatics tool development. The company’s mission is to improve the safety and efficacy of vaccines and protein therapeutics, while working to improve human health everywhere.     1998  EpiVax...